HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Volume 20, Volume 2, February 2016 Biomedical Research Governance       » Tissue banking in Singapore — An Evolving Enterprise       » China Recognizes Prominent Scientists and Stresses on Innovation       » NUS Researchers Uncover Potent Parasite-killing Mechanism of Nobel Prize-Winning Anti-Malarial Drug       » A New Water Robot "Born" to Detect Water Quality       » Probing the Mystery of How Cancer Cells Die       » Researchers Find Link between Processed Foods and Autoimmune Diseases       » Unravelling the Genetics of Pregnancy and Heart Failure      
INSIDE INDUSTRY
Scotland Demonstrates its Collaborative Approach to Cell Therapy Development
Scotland's leading industry players, Sistemic and Roslin Cells, will be working together with Scottish Development International to make the process of undertaking clinical trials in cell therapy easier, faster and more successful in reaching commercial realization. By bringing together unique Scottish investments such as Health Sciences Scotland, NHS Research Scotland, NHS Scotland and leading technology-based industrial partners, the country believes it can offer cell therapy companies a streamlined process for clinical trials. This will not only provide access to the right patients, but will support product development, characterization and potency development, making the regulatory process much easier.

$120 million has been invested into the Scottish stem cell cluster since 2004 to build state of the art clinical infrastructure and fund essential projects for this industry, such as manufacturing GMP grade hESC. Its commercial landscape has developed some of the most promising advancements in enabling technologies that have helped guide cell functionality and have created viable cell therapy products fit for the clinic. Scotland was selected as the location to conduct the UK's first approved ATMP stem cell clinical trial and already has active cell therapies in clinical practice, which include a pancreatic islet transplantation programme for Type 1 Diabetes and EBV Cytotoxic T Lymphocyte (CTL) bank for post-transplant lympho-proliferative disease.

"Thanks to the outstanding collaboration across NHS, academia, government and industry, Roslin Cells has been able to accelerate the expansion of its cell therapy manufacturing facilities based in the Scottish Centre for Regenerative Medicine. We and our NHS partners are working on the development of a number of cellular therapies which will enter clinical trial within Scotland and Europe in the coming years. This pipeline of new therapies demonstrates the exceptional resources Scotland has to offer," Roslin Cells' CEO, Aidan Courtney said.

The supportive regulatory environment in Scotland including high ethical standards for stem cell research activities, has ensured cell therapy companies have a streamlined clinical research approach that ultimately enables new medicines to get to market faster.

"Understanding the cell therapy products being placed into trial as well as selecting the right patient population is essential to conducting a successful clinical trial. Sistemic's SistemQC™ technology is already helping some of the world's leading cell therapy companies to achieve this and it seems fitting that, as a company founded in Scotland, we work with Scottish Development International, NHS Scotland and other leading companies to make Scotland the go to place for conducting trials in cell therapy of the highest caliber," Sistemic's CEO Jim Reid explained.

Click here for the complete issue.

NEWS CRUNCH  
news EmTech Asia Opens: Features 50 speakers on innovation and emerging technologies
news Russia's only project to supply local high-tech anti-cancer drugs abroad continues with the first shipment to Vietnam
news Wheat Genome Sequencing Gets Major Boost
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Primates in Biomedical Research
COLUMNS  
\
APBN Editorial Calendar 2016
January:
Guest Editorial - Biotechnology In Korea
February:
Guest Editorial - Biomedical Research Governance
March:
Guest Editorial - Life-Saving Opportunities: A Guide to Regenerative Medicine
April:
Cancerology / Oncology
May:
Guest Editorial - Antibody Informatics In Japan
June:
Medical Devices and Technology
July:
Water Technology
August:
Occupational Health
September:
Olympics: Evolution of Sports
October:
Respiratory: Seasonal flu viruses
November:
Tobacco Smoking
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» Editorial Enquiries: biotech_edit@wspc.com
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   Ms PoPo Kwok or Ms Sok Ching Lim/td>
Copyright© 2015 World Scientific Publishing Co Pte Ltd  •  Privacy Policy